CRL vs. MRNA: Charles River Laboratories vs. Moderna Stock Comparison
How do Charles River Laboratories (CRL) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Charles River Laboratories (CRL) and Moderna (MRNA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but CRL is classified in Life Sciences Tools & Services while MRNA is classified in Biotechnology.
| Profile Item | CRL | MRNA |
|---|---|---|
| Name | Charles River Laboratories International, Inc. | Moderna Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Biotechnology |
| GICS Sub-Industry | Life Sciences Tools & Services | Biotechnology |
| Market Capitalization | 16.17 billion USD | 101.48 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 23, 2000 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | CRL | MRNA |
|---|---|---|
| Total Return (1Y) | 110.83% | 1,031.66% |
| Total Return (3Y, Annualized) | 27.87% | 58.68% |
| Total Return (5Y, Annualized) | -1.57% | 3.23% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | CRL | MRNA |
|---|---|---|
| Volatility (1Y, Annualized) | 47.81% | 194.88% |
| Beta (5Y) | 1.33 | 1.08 |
| Max Drawdown (5Y) | -74.73% | -93.93% |
| Avg. Volume (3M) | 1.05M | 21.61M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | CRL | MRNA |
|---|---|---|
| Sharpe Ratio (1Y) | 2.23 | 5.27 |
| Sortino Ratio (1Y) | 3.58 | 20.44 |
Profitability
ROE (TTM)
Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.27%
- Max
- 109.18%
- Q3
- 6.23%
- CRL
- 1.27%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.00%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- MRNA
- -39.00%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01%
- Max
- 18.05%
- Q3
- 4.78%
- CRL
- 1.01%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-141.43%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- MRNA
- -141.43%
Operating Margin (TTM)
Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Charles River Laboratories (CRL) reports 23.42%, ranking against industry peers normally.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.42%
- Max
- 83.12%
- CRL
- 23.42%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-557.93%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- MRNA
- -557.93%
Profitability Metrics
| Metric | CRL | MRNA |
|---|---|---|
| ROE (TTM) | 1.27% | -39.00% |
| ROA (TTM) | 4.74% | -13.26% |
| Net Margin (TTM) | 1.01% | -141.43% |
| Operating Margin (TTM) | 23.42% | -557.93% |
| Gross Margin (TTM) | 35.10% | -66.02% |
Growth
Revenue Growth
Both Charles River Laboratories (CRL) at -0.85% and Moderna (MRNA) at -39.92% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.
EPS Growth
Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.
Growth Metrics
| Metric | CRL | MRNA |
|---|---|---|
| Revenue Growth (YoY) | -0.85% | -39.92% |
| Revenue Growth (3Y CAGR) | 0.33% | -53.30% |
| EPS Growth (YoY) | -1,555.00% | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Both Charles River Laboratories (CRL) at 1.41 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.41
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- CRL
- 1.41
- Min
- 0.10
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.30
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRNA
- 2.30
- Min
- 0.10
Debt / Equity (MRQ)
Moderna (MRNA) at 0.19 carries an industry-typical debt-to-equity mix, while Charles River Laboratories (CRL) at 0.87 uses more debt funding than most peers.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.87
- Max
- 1.42
- CRL
- 0.87
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- MRNA
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | CRL | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 1.41 | 2.30 |
| Debt / Equity (MRQ) | 0.87 | 0.19 |
| Net Debt / EBITDA | 2.92 | -- |
Dividends
Dividend Yield (TTM)
Neither Charles River Laboratories (CRL) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Charles River Laboratories (CRL) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- CRL
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | CRL | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
366.87
- CRL
- 366.87
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- MRNA
- --
P/S Ratio (TTM)
Charles River Laboratories (CRL) at 4.07 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.07
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- CRL
- 4.07
- Q1
- 3.01
- Min
- 0.01
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.55
- Max
- 58.18
- MRNA
- 45.55
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Charles River Laboratories (CRL) at 5.01 is valued about in line with its industry on P/B ratio, while Moderna (MRNA) at 11.58 carries an above-peer premium to book — MRNA is pricier on assets.
CRL
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.01
- Max
- 13.53
- Q3
- 6.54
- CRL
- 5.01
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.58
- Max
- 13.53
- MRNA
- 11.58
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | CRL | MRNA |
|---|---|---|
| P/E Ratio (TTM) | 366.87 | -- |
| P/S Ratio (TTM) | 4.07 | 45.55 |
| P/B Ratio (MRQ) | 5.01 | 11.58 |
| Free Cash Flow Yield (TTM) | 2.74% | 0.29% |